Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first
Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.
Overview
Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.
Source
Originally published at www.cnbc.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.